The platform will combine AgaMatrix’s FDA-cleared Jazz Wireless 2 Bluetooth blood glucose monitoring tech with Glytec’s eGlycemic Management System, according to the companies.
The companies are developing a platform that can automatically transfer a patient’s blood glucose data from the AgaMatrix Diabetes Manager App to eGMS so that healthcare professionals can personalize a patient’s diabetes management plan.
The 2 companies reported that they are engaged in a pilot of the cloud-based platform.
“We have a legacy of developing unique monitoring solutions that leverage a connected platform to empower more people with diabetes to easily track and share their glucose data,” AgaMatrix president & CEO John Alberico said in prepared remarks. “The collaboration with Glytec further emphasizes our commitment to providing better technology to enable better diabetes therapy.”
“Currently, some 50% of all patients on insulin are not only above their target A1C goal, they’re also experiencing far too many avoidable episodes of hypoglycemia. Not surprisingly, the difficulties and costs associated with managing diabetes create major issues with medication adherence and discontinuation,” Glytec president & CEO Bob Leonard added. “Given the highly individualized complexities of basal and bolus insulin management, and the lack of dynamic tools available historically, there’s no reason anyone should have expected different results. The integrated AgaMatrix-Glytec solution provides clinicians easy-to-use, highly scalable, evidence-based decision support to more effectively and efficiently titrate patients in a virtual care fashion as opposed to waiting months between office visits to make insulin dosing adjustments. We’re excited to add AgaMatrix as a partner.”